Volanesorsen for treating familial chylomicronaemia syndrome
KEYWORDS: volanesorsen, committee, clinical, treatment, levels, patients, people, fcs, company, approach, model, risk, noted, erg, utility

TGs. The committee considered that the company's approach in allocating the utility values for the intermediate group was problematic. It concluded that the ERG's approach of linking utility values to TG levels and health states was acceptable for decision making. Utility for carers 4.28 The company included utility decrements for carers in the economic model, based on estimates from the literature. In the company's original base case, it used the values from NICE highly specialised technology submission (metreleptin for treating lipodystrophy) as a proxy for carers of people with FCS, assuming a 0.1 utility decrement for carers. In the evaluation consultation document, the committee and ERG highlighted concerns about the source of the proxy value and around the value itself. The committee asked the company to explore alternative values. 4.29 After consultation, the company presented an alternative utility value, decreasing the decrement from 0.1 to 0.04 in the updated model. The company explained that the decrement was a midpoint value between the effect on family utility for patients with new musculoskeletal conditions (0.03) and the utility decrement between treated and untreated groups (0.05) in the metreleptin submission. The company believed that this was a fair valuation of quality-adjusted life year
